In the News..

28-06-2006

NASA Chooses Sequencing Software from CLC bio

The Exobiology Branch of the NASA Ames Research Center in Moffett Field, California, has chosen bioinformatics software from CLC bio for analyzing sequencing data which revolves around hypersaline microbial mat systems that are found worldwide in exotic locations such as Baja, Mexico, and Solar Lake, Egypt, to name a few.

Chenomx 4.5

Introduction

Chenomx NMR Suite 4.0 is an integrated set of tools for identifying and quantifying metabolites in NMR spectra. By combining sophisticated chemistry with advanced algorithms, Chenomx NMR Suite 4.0 offers a metabolic profiling platform with unparalleled power and ease-of-use for use in metabolomics, drug discovery research or clinical diagnostics.

Application Areas

Chenomx technology can be applied to a wide variety of application areas. While currently focused on metabolomics and related applications, the fundamental technology is applicable to more general mixture analysis scenarios.

Pharmaceutical Research

Chenomx NMR Suite provides a much faster analysis of spectral data than can be derived by manual inspection. Chenomx NMR Suite is used in research laboratories to make the research effort more timely and cost efficient so you can dedicate your resources more effectively.

Pharmaceutical companies are under constant pressure to develop new drugs. Metabolic profiling allows researchers to link biochemicals to corresponding genes or proteins with relative ease. From these linkages, the detection and validation of potential drug targets can be accelerated.

Metabolomics can provide a rapid screening mechanism for the efficacy and safety of potential pharmaceutical agents.

• Monitoring the efficacy of potential drug candidates: Pharmaceutical agents that show significant effectiveness are given priority. Metabonomic studies may provide insight into the metabolic similarities between animal models and the human conditions that they are to simulate. These differences and similarities are yielding valuable information about the metabolic pathways and drug disposition.
• Identifying pathological reactions to potential drug candidates: Subtle changes in metabolic composition may flag a potentially harmful drug candidate before damage becomes permanent or symptomatic. The earlier in the drug development cycle that toxic side effects can be identified, the fewer resources are invested before the candidate drug is eliminated from the trial.
• Monitoring recovery from toxicological assault.
• Identifying biomarkers of clinical or toxicological significance.

Clinical Trials

Chenomx NMR Suite will dramatically streamline the evaluation of potential pharmaceutical drugs by enabling clinical trial personnel to identify toxic effects at the metabolite level long before the damage is manifested in clinical symptoms.

Metabolic profiling provides a noninvasive mechanism for monitoring the health of subjects involved in clinical trials.

• Monitoring the status of the subjects over the course of the trial.
• Providing a more holistic perspective of patient health than selective monitoring of individual biomarkers.
• Identifying potentially harmful regimes before irreversible damage occurs.
• Developing new models of pathology.

Diagnostics

Chenomx NMR Suite will dramatically streamline the evaluation of potential pharmaceutical drugs by enabling clinical trial personnel to identify toxic effects at the metabolite level long before the damage is manifested in clinical symptoms.

In the future, metabolic profiling will be used as a noninvasive mechanism for diagnosing and monitoring patient's overall health status. The more the sample deviates from the normal values, the more severe the condition that is being monitored.

• Monitoring patient health status over time.
• Diagnosing and monitoring disease.
• Providing valuable insights into disease and toxin mechanisms when combined with histopathology and microscopic data.